Platform
The Proprietary Mebias Discovery Platform 19Fluid
Detect fluid/solution dynamic conformation of full length GPCRs
-
- Proprietary purification of native, full-length GPCR
- Protein NMR with proprietary 19F labeling scheme to capture coupling of scaffold proteins (G-protein, beta-arrestin) to GPCR
Empowers drug discovery beyond current state of the art
Platform is agnostic to therapeutic area
Successfully applied to multiple targets
-
- MOR, DOR
- S1PR1
- β1AR, β2AR
- Additional GPCRs have been expressed and purified as potential targets (e.g., MLNR, A2A)
Uncovering extremely signaling-pathway selective mu-opioid receptor agonists
